BPOM Issues Marketing Authorisations for 43 TB Medicines Between 2024 and 2026
Jakarta (ANTARA) – The Food and Drug Monitoring Agency (BPOM) issued marketing authorisations for 43 tuberculosis (TB) medicines and approved 33 first generic medicines for various indications, including cancer, TB and diabetes, between 2024 and 2026.
BPOM chief Taruna Ikrar said in Jakarta on Saturday that these achievements formed part of efforts to expand treatment options and improve public access to medicines.
Taruna said the agency was committed to supporting the Government’s priority programmes through risk-based oversight of medicines and food, stronger cross-sector collaboration, and guidance for businesses and programme organisers.
“BPOM’s support for the Government’s agenda is demonstrated through concrete work to protect the public, ensure the safety of medicines and food, and foster the growth of a competitive industry,” Taruna said.
Regarding achievements during the first two years of President Prabowo Subianto and Vice-President Gibran Rakabuming Raka’s administration, BPOM said it had conducted pro-justitia investigations in 360 cases between 1 October 2024 and 20 October 2026, involving evidence valued at Rp335 million.
BPOM also recommended the removal of 451,791 online links selling illegal products and added 1,602 illegal products to its blacklist.
Internationally, BPOM’s recognition as a WHO-Listed Authority (WLA) in December 2025 marked an important milestone for the credibility of Indonesia’s medicines regulatory system. The recognition is also a foundation for strengthening global confidence in the country’s medicines oversight capacity and supporting the competitiveness of Indonesia’s pharmaceutical industry.
Health Minister Budi Gunadi Sadikin previously said the decline in TB incidence over the past two years was due to more aggressive screening and treatment to prevent transmission.
Other efforts to eliminate TB include treating close contacts of TB patients, conducting clinical trials of the M72 vaccine, and developing treatment regimens to shorten the treatment period from four to six months to just one month.
Source: jawawa.id (https://jawawa.id/newsitem/bpom-issues-marketing-authorisations-for-43-tb-medicines-between-2024-and-2026-1792813893)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5808959/bpom-terbitkan-izin-edar-bagi-43-obat-tb-selama-2024-2026), translated from Indonesian